Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$6.3MMiss by $9.5M
EPS-$0.22Beat by $0.08
Revenue estimate$15.8M
EPS estimate-$0.30

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$11.0M
EPS estimate-$0.25

Financials

Q1 2026

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$1.6B-41.6%
Enterprise value$1.02B-55.9%
P/S24.1×-18.3×

Profitability

See full
Gross margin7.2%—
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Segments

By product

See full
Operating revenue$6.3M-57.5%
Grant revenue$171.0K+334%

By segment

See full
Reportable Segment$6.5M-56.1%

Versus estimates

Revenue

Q1 2026$6.3MMiss by $9.5M
Q4 2025$35.4MBeat by $10.8MQ3 2025$5.2MMiss by $19.4MQ2 2025$19.1MMiss by $822.0KQ1 2025$14.7MBeat by $785.0KQ4 2024$4.5MMiss by $14.5M

Diluted EPS

Q1 2026-$0.22Beat by $0.08
Q4 2025-$0.21Beat by $0.07Q3 2025-$0.36Beat by $0.02Q2 2025-$0.41Miss by $0.06Q1 2025-$0.50Miss by $0.06Q4 2024-$0.53Miss by $0.09

Ask the moment Recursion Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Recursion Pharmaceuticals, Inc. report Q1 2026 earnings?
Recursion Pharmaceuticals, Inc. (RXRX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Recursion Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Recursion Pharmaceuticals, Inc. reported revenue of $6.3M and eps of $-0.22 for Q1 2026.
Did Recursion Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $15.8M by $9.5M. EPS beat the consensus estimate of $-0.30 by $0.08.
How did Recursion Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 57.3% from $14.7M a year earlier and eps grew 56.0% from $-0.50.
Where can I find Recursion Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001601830-26-000077) and the 10-Q periodic report (0001601830-26-000078) directly on SEC EDGAR. The filing index links above go to sec.gov.